XOMAO
NASDAQ
US
XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock
$25.64
▼ $-0.33
(-1.25%)
Vol 5K
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$329.3M
P/E
15.2
ROE
23.6%
Margin
45.9%
D/E
100.71
Beta
0.83
52W
$18–$40
Wall Street Consensus
11 analysts · Apr 20263
Strong Buy
6
Buy
2
Hold
0
Sell
0
Strong Sell
81.8%
Buy Rating
Price Chart
Similar Stocks
IMRX
Immuneering Corp
$424.9M
PBYI
Puma Biotechnology Inc
P/E 8.1
$299.8M
DMAC
DiaMedica Therapeutics Inc
$414.5M
CABA
Cabaletta Bio Inc
$210.8M
XOMA
Xoma Royalty Corp
P/E 15.2
$329.3M
IRD
Opus Genetics Inc
$138.6M
XFOR
X4 Pharmaceuticals Inc
$349.7M
NGNE
Neurogene Inc
$319.1M
FBRX
Forte Biosciences Inc
$341.6M
SRZN
Surrozen Inc
$193.7M
Earnings
Beat rate: 80.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.16 | $0.26 | +$0.42 |
| Sep 2025 | $-0.04 | $0.70 | +$0.74 |
| Jun 2025 | $-0.23 | $0.44 | +$0.67 |
| Mar 2025 | $-0.30 | $0.06 | +$0.36 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -11.2% | -13.0% | -11.2% | -11.2% | -11.2% | 23.6% |
| P/E (TTM) | — | — | — | — | — | 15.21 |
| Net Margin | 70.0% | -26.7% | -21.5% | -21.5% | -21.5% | 45.9% |
| Gross Margin | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| D/E Ratio | 123.17 | 134.27 | 123.17 | 123.17 | 123.17 | 100.71 |
| Current Ratio | 4.88 | 5.54 | 4.88 | 4.88 | 4.88 | 3.91 |
Key Ratios
ROA (TTM)
9.4%
P/S (TTM)
6.99
P/B
3.8
EPS (TTM)
$1.09
CF/Share
$-2.74
Rev Growth 3Y
-9.3%
52W High
$39.92
52W Low
$18.35
$18.35
52-Week Range
$39.92
How does XOMAO compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
XOMAO valuation vs Biotechnology peers
P/E ratio
15.2
▼
19%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
7.0
▼
46%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
3.8
▲
54%
above
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
XOMAO profitability vs Biotechnology peers
ROE
23.6%
▲
135%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
45.9%
▲
116%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
100.0%
▲
27%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
9.4%
▲
120%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
XOMAO financial health vs Biotechnology peers
D/E ratio
100.7
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
3.9
▼
12%
below
peers
(4.4)
vs Peers
vs Industry
In line
Beta
0.8
▼
15%
below
peers
(1.0)
vs Peers
vs Industry
Less volatile
XOMAO fundamentals radar
XOMAO
Peer median
Industry
XOMAO profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
XOMAO vs peers: key metrics
Latest News
No related news yet